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Recent work has highlighted a number of compounds that target bacterial virulence by affecting gene
regulation. In this work, we show that small-molecule inhibitors affect the expression of the type III secretion
system (T3SS) of Escherichia coli O157:H7 in liquid culture and when this bacterium is attached to bovine
epithelial cells. Inhibition of T3SS expression resulted in a reduction in the capacity of the bacteria to form
attaching and effacing lesions. Our results show that there is marked variation in the abilities of four
structurally related compounds to inhibit the T3SS of a panel of isolates. Using transcriptomics, we performed
a comprehensive analysis of the conserved and inhibitor-specific transcriptional responses to these four
compounds. These analyses of gene expression show that numerous virulence genes, located on horizontally
acquired DNA elements, are affected by the compounds, but the number of genes significantly affected varied
markedly for the different compounds. Overall, we highlight the importance of assessing the effect of such
“antivirulence” agents on a range of isolates and discuss the possible mechanisms which may lead to the
coordinate downregulation of horizontally acquired virulence genes.
Outbreaks of enterohemorrhagic Escherichia coli (EHEC)
infection occur sporadically in both the developed world and
the developing world, causing diarrheal disease that can
progress to hemorrhagic colitis and hemolytic-uremic syn-
drome (22). E. coli O157:H7 is the dominant serotype in North
America, parts of Europe, and Japan, and its pathogenicity has
been studied extensively at the molecular level. A number of
key virulence factors are known to be required for disease
progression, including the Shiga toxins and the type III secre-
tion (T3S) system (T3SS) required for characteristic attaching
and effacing (A/E) lesion formation (13). The T3SS is encoded
in a locus of enterocyte effacement (LEE) pathogenicity island
containing 41 genes in five main operons (18). Deletion of the
LEE4 operon prevents A/E lesion formation and colonization
of the terminal rectum, the principle colonization site in cattle
(24). Thus, vaccines that target the EHEC T3SS are being
developed for use in cattle (28). Furthermore, given the central
role of the T3SS in bovine colonization, it is highly likely that
inhibition of a functional T3SS could prevent colonization of
humans, thereby limiting disease.
As the prevalence of antibiotic-resistant strains increases,
compounds that target virulence determinants of pathogenic
bacteria have become an increasingly attractive alternative to
bactericidal antibiotics. The major advantage of these com-
pounds is their significantly less positive selection for resistant
mutants as the nonpathogenic normal flora is not affected by
treatment (14). A class of such “virulence blockers” that inhibit
T3SS in Yersinia spp. has been described, and these com-
pounds have been shown to be broadly effective against a
number of pathogenic bacteria that utilize T3SS, including
Chlamydia spp., Salmonella enterica serovar Typhimurium, and
enteropathogenic E. coli (EPEC). The mechanism of inhibi-
tion in each organism is not completely understood. However,
it is clear that transcription of T3S genes in these pathogens is
reduced. Whether this is due to feedback from the T3S ma-
chinery or due to direct effects on transcription factors remains
to be determined. Treatment of bacteria with micromolar
concentrations of inhibitors is sufficient to reduce Salmo-
nella serovar Typhimurium invasion of cultured epithelial
cells and induction of enteritis in vivo (11), to arrest matu-
ration of Chlamydia sp. inclusions (36), and to reduce pro-
liferation of Yersinia pseudotuberculosis (25). Further experi-
ments have shown that the antichlamydial activity of this family
of inhibitors can be reversed by addition of iron, suggesting
that the activity of these compounds may be linked to iron
availability in the cell, although the mechanisms behind this
reversal are unknown. In Vibrio cholerae a “virulence blocker”
that reduces expression of cholera toxin and the toxin-coregu-
lated pilus has been described. This inhibitor has been shown
to act by posttranslationally inactivating the AraC family reg-
ulator ToxT, suggesting that regulators of virulence genes may
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be an important target for this class of inhibitors (35). A recent
study has also shown that a structurally distinct compound,
LED209, can prevent phosphorylation of the E. coli O157
QseC membrane protein, a sensor of host adrenergic mole-
cules (30). The inhibition of QseC function leads to impaired
expression of virulence factors and affects colonization of tis-
sue culture cells by downregulation of Ler, the master regula-
tor of the T3SS of E. coli O157 (30). Of particular importance
to this study is a previous report that described screening of
virulence blockers in EPEC (9). This previous report showed
that addition of a compound with structural similarity to the
compounds described in this work transcriptionally downregu-
lated the major operons of the EPEC LEE. However, the
extent to which other genes were affected was not examined.
Here we characterize the effects of four structurally related
salicylidene acylhydrazide virulence blockers on global gene
expression in E. coli O157:H7. Our analyses show that tran-
scriptional repression of the T3SS is accompanied by repres-
sion of virulence genes encoded on mobile genetic elements,
demonstrating that there are global effects on virulence gene
regulation. We also show that these inhibitors effectively re-
duce formation of actin pedestals in vitro.
MATERIALS AND METHODS
Bacterial strains and plasmids. Unless otherwise stated, all experiments were
performed using E. coli O157:H7 strain TUV-930, a Shiga toxin-negative deriv-
ative of strain EDL933 (3). To examine the effects of inhibitors on a range of
strains and phage types (PTs), six additional E. coli O157 strains were used: ZAP
3 (PT 2), ZAP 11 (PT 21/28), ZAP 12 (PT 21/28), ZAP 229, (PT 2), ZAP 231 (PT
4), and ZAP 243 (PT 8). The green fluorescent protein (GFP) reporter plasmids
pAJR71 to pAJR75 used in this study have been described previously (32, 33).
Inhibitors and media. Compounds ME0052 to ME0055 (Fig. 1), which were
selected on the basis of their ability to inhibit the T3SS of related pathogens (2,
25, 36), were prepared and supplied by Mikael Elofsson. These compounds have
been described previously using different names, as follows: ME0052, INP0010
and compound 8; ME0053, INP0403 and compound 11; ME0054, INP0401 and
compound 10; and ME0055, INP0031 and compound 17 (25). Stock solutions
were prepared in dimethyl sulfoxide (DMSO), aliquoted, and stored at 20°C in
the dark. The final DMSO concentration added to the bacteria was less than
2% in all experiments. Minimal essential medium with HEPES modification
(MEM-HEPES) (Sigma M7278) was used in this study to promote expression
of the LEE pathogenicity island. This medium was supplemented with 250
nM Fe(NO3)2 and glucose at a final concentration of 0.2%. Antibiotics were
included when they were required at the following concentrations: 12.5 g  ml1
chloramphenicol and 25 g  ml1 kanamycin. To examine the effects of higher
concentrations of iron on the effects of the inhibitors, 200 M FeSO4 was added
to the growth medium where indicated below.
Protein secretion and Western blot analyses. Bacteria were cultured overnight
in LB and diluted to obtain an optical density at 600 nm (OD600) of 0.05 in
prewarmed MEM-HEPES supplemented with 250 nM Fe(NO3)2 and glucose
(final concentration, 0.2%). When required, the specific growth rate was reduced
by addition of 0.1 M or 0.2 M NaCl to this medium. Cultures were grown at
37°C to an OD600 of 0.8, and then the secreted proteins were extracted by
trichloroacetic acid precipitation as described previously (34). For protein
localization experiments, whole-cell fractions were prepared by centrifuga-
tion (20 min, 4,000  g), washed twice in 20 ml phosphate-buffered saline
(PBS), sonicated, and resuspended in 400 l protein A buffer (34). Proteins
were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
and Western blotting for Tir, EspD, and GroEL was carried out as described
previously (34). The Western blots were quantified using Scion image soft-
ware, which allowed comparisons of different samples.
Transcriptomics. Transcriptional profiling of cultures treated with the inhib-
itors was carried out essentially as described previously (33). In brief, overnight
cultures of E. coli TUV-930 were grown in MEM-HEPES (Sigma) supplemented
with 250 nM Fe(NO3)2 and glucose (final concentration, 0.2%) and then diluted
to obtain an OD600 of 0.1 in the same medium. An inhibitor was added to test
cultures at a final concentration of 20 M, and an equal volume of DMSO was
added to reference cultures. At an OD600 of 0.8, 15-ml cultures were stabilized
using an equal volume of RNAprotect (Qiagen), and RNA was extracted using
a Qiagen RNeasy mini kit. Contaminating DNA was removed by DNase I
treatment (Ambion). The total RNA was assessed to determine its quality and
was quantified using an Aglient 2100 bioanalyzer. Synthesis of cDNA and label-
ing of total RNA were performed using an Amersham CyScribe postlabeling kit
according to the manufacturer’s instructions. The cDNA was hybridized to 70-
mer spotted oligonucleotide arrays containing open reading frames from E. coli
K-12, E. coli Sakai VT2, and E. coli EDL933 (University of Birmingham, United
Kingdom) using a Genomic Solutions GeneTac hybridization machine. Hybrid-
ized slides were scanned using a Genepix 4000A scanner and GenePix 7.0
software (Axon Instruments, Union City, CA). Data were analyzed using Gene-
spring GX 7.3.1 (Agilent).
Regulon analysis for global regulators. In order to determine if posttransla-
tional modification of regulators contributed to regulation by ME0052 to
ME0055, the regulons for nucleoid structuring protein (H-NS), LexA, Fur, and
PchA were defined using previously described data and analyzed using Gene-
spring 7.3.1. The H-NS, LexA, and Fur regulons have not been elucidated for E.
coli O157 but have been described for E. coli K-12, and they provide an indicator
of the activity in the E. coli common backbone. The H-NS regulon has been
described previously by Oshima et al. (26), and the LexA regulon has been
described for E. coli K-12 using transcriptomics and chromatin immunoprecipi-
tation studies (39). For both of these regulons, E. coli K-12 gene designations
were converted to O157 “z” numbers using Genespring 7.3.1 and by BLAST
analysis. The Fur regulon has been described by Gama-Castro et al. (8) and was
acquired from RegulonDB (http://regulondb.ccg.unam.mx/), and the gene des-
ignations were similarly converted to “z” numbers using Genespring 7.3.1 and
BLAST. The PchA and Ler regulons were recently defined by transcriptomics
and chromatin immunoprecipitation studies for E. coli O157 strain Sakai, a
sequenced O157 outbreak strain from Japan. The Sakai PchA and Ler regulons
were converted to EDL933 gene designations using the nucmer genomic align-
ment tool at coliBASE (http://xbase.bham.ac.uk/colibase/) and by BLAST anal-
ysis. Analyses of overlaps between these regulons and genes affected by inhibitor
treatment were performed using Genespring 7.3.1.
Determination of LEE expression using GFP reporter fusions. Expression of
the LEE was determined by using a series of plasmid-based promoter::GFP
reporter fusions described previously (pAJR71 to pAJR75) (34). To measure
population fluorescence, triplicate 100-l aliquots of transformed bacteria were
FIG. 1. Structures of ME0052, ME0053, ME0054, and ME0055.
The compounds have been previously described using different names,
as follows: ME0052, INP0010 and compound 8; ME0053, INP0403 and
compound 11; ME0054, INP0401 and compound 10; and ME0055,
INP0031 and compound 17.
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dispensed into 96-well black microtiter plates and analyzed using a BMG Fluo-
star plate reader at 37°C. The OD600 of cultures were used to monitor growth.
Fluorescence was plotted against optical density using Microsoft Excel software,
and the line of best fit was obtained. The promoterless plasmid pAJR70 (34) was
employed to correct for the background fluorescence of the strain and medium.
Comparisons between treated cultures and cultures treated with DMSO alone
were made using an OD600 of 0.8 to obtain the best comparison with the data
obtained by transcriptomics.
Fluorescence microscopy analysis of LEE1 and flagellum expression. Embry-
onic bovine cells (German Collection of Microorganisms and Cell Cultures no.
ACC192) were prepared and cultured as described previously (32). TUV-
930(pAJR71) (LEE1::GFP) was grown in MEM-HEPES to an OD600 0.6 at 37°C
with 20 M ME0055 or the same volume of DMSO. Bacteria were added to a
multichamber slide and incubated at 37°C. Samples were fixed at intervals by
removing portions of the culture and adding 4% paraformaldehyde (PFA).
Flagellum expression was detected as described previously (10). The adherent
bacteria were stained with rabbit anti-O157 and anti-H7 polyclonal antiserum
(diluted 1:500 in PBS; Mast Diagnostics) at room temperature for 30 min,
washed, and then incubated with tetramethyl rhodamine isocyanate (TRITC)-
labeled secondary antibody (anti-rabbit antibody diluted 1:1,000; Sigma). The
time points analyzed were 60, 120, 180, and 300 min after addition of bacteria. To
measure single-cell expression by fluorescence microscopy, a z stack of 20 images
with a spacing of 0.1 m was captured with a Zeiss Axioimager M1 fluorescence
microscope equipped with a Hamamatsu ORCA AG camera using Volocity
software (Improvision). These images were used to create a composite image
that reduced the spatial effects of bacteria in different focal planes. GFP intensity
was determined using Volocity software with a threshold of 2,000 relative fluo-
rescence units as the cutoff point to separate “GFP-positive” and “GFP-nega-
tive” bacteria.
Detection and quantification of A/E lesions. To detect host cell actin, cells
were permeabilized using 0.2% Triton X-100 and then treated for 20 min at
room temperature with TRITC-phalloidin (5 g  ml1; Sigma), washed twice
with PBS, and mounted in fluorescent mounting medium (Dako). Improvision
Volocity software (Quantification) was used to examine three independent rep-
licates with sampling of 15 separate fields per replicate. Bacteria and areas of
concentrated actin were identified using size and the fluorophore as selection
parameters. The percentage of total bacteria in each field associated with con-
densed actin was then determined.
Array data accession number. The MIAME-compliant array data have been
deposited in the Gene Expression Omnibus (GEO) database at NCBI under
GEO accession number GSE10319.
RESULTS
Effects of salicylidene acylhydrazide inhibitors on the growth
rate. In our initial work we aimed to determine the effects of the
compounds studied on the bacterial growth rate. We were
aware that marked changes in the growth rate result in changes
in global gene expression, making any specific effects of the
compounds hard to determine. Bacteria were cultured in
MEM-HEPES containing a range of concentrations (10 to 50
M) of the four compounds. At both 10 and 20 M we ob-
served only minor changes in the growth rate (Table 1) for all
four compounds. Addition of a higher concentration (50 M)
of the compounds had more marked effects on the specific
growth rate (Table 1). We therefore focused on the 20 M
concentration to minimize any effects of an altered growth rate
on gene expression.
Effects of salicylidene acylhydrazide inhibitors on secretion
of T3SS effector proteins. In order to characterize the effects of
the four inhibitors on the secretion of effector proteins by the
T3SS, total secreted proteins were prepared from strain TUV-
930 cultured in MEM-HEPES containing an inhibitor at a
concentration of 20 M or the equivalent volume of DMSO.
The secreted protein profiles were analyzed by colloidal blue
staining of the total secreted proteins produced by the bacteria,
as well as by Western blotting to quantify both the whole-cell
expression and secretion of the translocated intimin receptor
(Tir). Addition of the compounds at a concentration of 20 M
resulted in inhibition of Tir expression by all four compounds;
ME0053 and ME0055 were the most effective inhibitors, re-
ducing the Tir expression in the whole-cell fraction by 90%
(Fig. 2). Analysis of the secreted fractions showed that there
was no detectable Tir when the bacteria were treated with
ME0055, which correlates with the major reduction in whole-
cell expression with this compound. Treatment with ME0053
resulted in a reduced but detectable signal, implying that, while
whole-cell expression of Tir was reduced, Tir secretion was not
strongly inhibited. ME0052 and ME0054 were less effective,
reducing Tir expression by 39% and 54%, respectively. Treat-
ment with ME0054 resulted in strong inhibition of Tir secre-
tion, whereas treatment with ME0052 did not appear to reduce
the secretion of Tir and the secreted fraction correlated closely
with the whole-cell fraction.
FIG. 2. ME0052, ME0053, ME0054, and ME0055 inhibit expres-
sion and secretion of the effector proteins Tir and EspD from E. coli
O157:H7. Secreted (S/N) and whole-cell (W/C) fractions were pre-
pared from bacteria cultured in MEM-HEPES. Samples were sepa-
rated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and analyzed by Western blotting. The antibodies used for the blots
are indicated on the left (-Tir, anti-Tir antibody; -EspD, anti-EspD
antibody; -GroEL, anti-GroEL antibody). To examine the effect of a
decreased growth rate on Tir secretion, E. coli O157:H7 was cultured
in the absence (N/A) or presence of NaCl, and secreted Tir was
detected by Western blotting. The concentrations of NaCl added are
indicated above the blots.
TABLE 1. Growth rates of strain TUV-930 with and
without inhibitors
Compound Concn(M)
Specific growth rate
(h1, mean  SD)
% Growth
inhibition
None 0.54  0.01
ME0052 10 0.49  0.01 10
ME0052 20 0.44  0.01 12
ME0052 50 0.37  0.02 46
ME0053 10 0.49  0.02 10
ME0053 20 0.44  0.01 12
ME0053 50 0.06  0.01 900
ME0054 10 0.54  0.03 0
ME0054 20 0.50  0.02 8
ME0054 50 0.49  0.01 10
ME0055 10 0.54  0.02 0
ME0055 20 0.50  0.02 8
ME0055 50 0.44  0.03 12
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The same samples were also tested to determine the levels of
the translocator protein EspD, which is transcribed from a
different operon in the LEE. Addition of ME0054 or ME0055
resulted in strong inhibition of whole-cell EspD expression
(95% reduction) and corresponding low (ME0054) or unde-
tectable (ME0055) levels of EspD in the supernatant fraction
(Fig. 2). ME0053 blocked whole-cell expression less effectively,
although the level of secreted EspD was markedly reduced by
this inhibitor. ME0052 was the least effective inhibitor, and
both whole-cell expression and the secreted levels showed re-
ductions similar to those observed for Tir.
These data were confirmed by colloidal blue visualization of
the total secreted proteins, which showed that there was a
concentration-dependent inhibitory effect on the overall secre-
tion profile that varied with the compound; ME0055 was the
most effective inhibitor, followed by ME0054, ME0053, and
ME0052 (data not shown). As a control, intracellular GroEL
levels were also assessed by Western analysis (Fig. 2). The
results showed that the four compounds did not affect general
protein expression or stability, and less than 15% variation
between the samples was observed.
To examine if the observed inhibition of translocator and
effector protein expression and secretion was due to the slight
reduction in the bacterial growth rate caused by addition of the
compounds, we tested the relationship between the growth
rate and the secretion phenotype. To reduce the bacterial
growth rate independent of the salicylidene acylhydrazide in-
hibitors, NaCl was added to increase the osmolarity of the
growth medium. Compared to the data for bacteria cultured in
MEM-HEPES alone, addition of NaCl resulted in an increase
in Tir protein secretion (Fig. 2). Additional of 0.1 M NaCl
reduced the bacterial growth rate by 18% (data not shown) and
increased the level of secreted Tir by 34% (Fig. 2). Addition of
0.2 M NaCl reduced the growth rate by 44%, which led to a
61% increase in the level of Tir secretion. These data suggest
that the decrease in the growth rate after addition of the
salicylidene acylhydrazide inhibitors is unlikely to account for
the inhibition of T3S.
To examine if the compounds acted with a range of strains,
six other E. coli O157 isolates were tested with all four com-
pounds (Table 2). These isolates included three isolates from
human outbreaks (ZAP 229, ZAP 231, and ZAP 243) and
three isolates obtained from bovine samples (ZAP3, ZAP 11,
and ZAP 12). These strains have four different PTs (PTs 2, 4,
8, and 21/28), all commonly associated with disease outbreaks
in the United Kingdom. For these assays, variations in the
extent of inhibition of secretion were determined by blotting
for secreted Tir (Table 2). While addition of ME0052 was
largely ineffective with TUV-930, it resulted in inhibition of Tir
secretion in the six strains mentioned above (Table 2). Addi-
tion of ME0053 resulted in inhibition of TUV-930 and the six
other strains, but the extent of inhibition varied considerably.
ME0054 was the most effective inhibitor for the entire strain
collection. In comparison, ME0055, which was highly effective
with four strains, was far less inhibitory when it was tested with
ZAP229, ZAP231, and ZAP243 and reduced Tir secretion by
only 43 to 60% (Table 2).
Analysis of transcriptional changes resulting from inhibitor
addition. In an effort to understand the molecular mechanism
by which the inhibitory compounds function, we carried out
transcriptional profiling experiments. Strain TUV-930 was
grown to an OD600 of 0.8 in MEM-HEPES in the presence or
absence of an inhibitor at a concentration of 20 M, and RNA
was harvested and labeled for microarray analysis. Table 3
shows the cumulative results for genes with 2-fold changes
with all four inhibitors. The data show that all four inhibitors
reduce the expression of all genes in the LEE (Fig. 3). In
addition to repressing the LEE, all of the inhibitors tested also
repressed transcription of the non-LEE effectors nleA, espJ,
and espN and pO157 open reading frames L7027 and L7037.
The inhibitors predominantly repressed gene expression, and
they varied in the total number of genes that they affected. For
example, using a cutoff of a 3-fold change in transcription,
ME0052 significantly (P  0.05) affected the transcription of
181 genes, whereas ME0055 significantly affected the tran-
scription of 24 genes (Tables 3 and 4; see Table S1 in the
supplemental material).
Repression of cryptic prophage genes was observed for
all inhibitors, and 52% (ME0052), 57% (ME0053), 78%
(ME0054), and 19% (ME0055) of the affected genes were on
a cryptic prophage (Table 4). Genes with 2-fold or 3-fold
changes for each inhibitor were found to be significantly biased
toward laterally acquired O-island (OI) DNA (27) for com-
pounds ME0052, ME0053, and ME0054, as determined using
a chi-square test (P  0.0001) (Table 4). The level of signifi-
cance for ME0055 fell short of this level, probably due to the
small subset of genes affected by this compound.
The finding that the transcriptional changes induced by the
salicylidene acylhydrazide compounds are biased toward a
subset of OI genes suggested that a global regulator of
horizontally acquired DNA was affected by these inhibitors.
We therefore examined the array data to determine if any of
the established regulators of the LEE and other horizontally
acquired genes was affected by the compounds. Seventeen
previously characterized regulators (for a review, see reference
19) were analyzed to determine if addition of the compounds
resulted in transcriptional changes in their expression. For
several of these regulators, the analysis was expanded to ex-
amine the genes known to be controlled by them. Figure 4
shows the effects of all four compounds on the regulators. It is
clear that the majority of the genes (hha, sdiA, recA, rpoS, qseA,
fis, yhiF, yhiE, lexA, and hns) showed no marked changes in
transcription. To examine if the compounds could affect the
TABLE 2. Relative inhibition of T3S by salicylidene acylhydrazide
compounds in different E. coli O157 strains
Strain Source PT
% Inhibition witha:
ME0052 ME0053 ME0054 ME0055
TUV-930 Human NTb 23 68 98 99
ZAP3 Bovine 2 100 100 100 100
ZAP11 Bovine 21/28 100 100 100 100
ZAP12 Bovine 21/28 100 100 100 100
ZAP229 Human 2 80 59 97 60
ZAP231 Human 4 79 75 95 43
ZAP243 Human 8 86 94 91 44
a The amount of secreted Tir effector protein was determined by Western
analysis and compared to the amount for the strain cultured in DMSO alone to
determine the percentage of inhibition. Therefore, 100% inhibition was com-
plete inhibition of Tir secretion.
b NT, not typed.
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regulators posttranscriptionally, the regulons of H-NS, LexA,
and RecA were examined.
The histone-like H-NS protein is a pleiotropic regulator of
gene expression that plays an important role in transcriptional
inactivation of horizontally acquired DNA (7, 23). We used the
E. coli K-12 H-NS regulon described by Oshima et al. (26) to
look for transcriptional changes in the E. coli K-12 “backbone”
(genes that are common to both K-12 and O157) that would be
indicative of changes in H-NS regulation. We found that 10 of
the 63 genes affected by deletion of H-NS were significantly
(P  0.05) up- or downregulated at least twofold; however, the
majority of the regulon genes (53 genes) were not affected by
addition of an inhibitor (see Fig. S1A and B in the supplemen-
tal material). These data suggest that the compounds do not
function by affecting global H-NS regulation.
LexA and RecA mediate the SOS response to DNA damage
in E. coli K-12. The SOS response is known to be a key regu-
lator of lambdoid bacteriophage transcription as RecA stimu-
lates autocleavage of the phage repressor, cI, in response to
DNA damage, triggering a cascade that leads to transcription
of the Q antiterminator transcript and the lytic cycle. LexA has
also been shown to regulate the LEE in EPEC, placing both
the LEE and potentially phage-regulated transcripts under the
control of the SOS response (21). However, transcripts in the
TABLE 3. Genes with 2-fold changes with all inhibitor treatments (P  0.05; Benjamini-Hochberg false discovery rate)
in three of four experimentsa
Systematic
name
Common
name
OI
no. Effector
Mobile
element
Presence of
Ler and PchA
ME0052 ME0053 ME0054 ME0055
Ratio P value Ratio P value Ratio P value Ratio P value
L7027 L7027 pO157 0.361 3.08E03 0.483 1.62E01 0.328 5.89E02 0.337 8.44E02
L7031 L7031 pO157 Regulator 0.141 1.27E03 0.464 3.68E02 0.151 1.05E01 0.32 6.75E02
Z0955 Z0955 36 CP-933K PchA  Ler 0.083 2.13E04 0.214 4.11E02 0.096 9.60E02 0.155 6.75E02
Z1823 Z1823 50 CP-933N PchA 0.277 3.70E05 0.349 8.09E02 0.298 4.37E02 0.218 2.86E05
Z1824 Z1824 50 espN CP-933N PchA 0.147 5.33E04 0.214 1.42E03 0.17 7.79E03 0.435 3.50E04
Z2478b pspD 3.648 6.53E05 2.338 6.46E02 2.45 1.03E01 3.567 5.04E03
Z2479b pspC 3.9 5.05E05 2.444 5.19E02 2.512 9.44E02 3.97 7.69E03
Z3071 Z3071 79 espJ CP-933U PchA  Ler 0.152 3.49E04 0.236 9.20E03 0.168 3.01E03 0.478 2.45E01
Z3572 argT 0.494 1.35E03 0.492 1.00E01 0.387 1.48E02 0.262 6.02E03
Z5100 espF 148 espF1 CP-933L Ler 0.126 8.48E03 0.452 4.74E04 0.145 1.70E01 0.268 8.42E02
Z5102 Z5102 148 CP-933L Ler 0.062 4.34E03 0.357 2.87E05 0.103 1.92E01 0.125 5.12E02
Z5103 escF 148 CP-933L Ler 0.044 1.85E03 0.306 3.23E05 0.087 1.54E01 0.162 7.38E02
Z5104 Z5104 148 CP-933L Ler 0.045 1.80E03 0.305 5.35E04 0.085 1.48E01 0.138 5.03E02
Z5105 espB 148 espB CP-933L Ler 0.037 1.01E03 0.216 3.90E02 0.071 1.16E01 0.122 7.56E02
Z5106 espD 148 CP-933L Ler 0.033 3.62E03 0.261 5.87E02 0.072 1.17E01 0.061 4.71E02
Z5107 espA 148 CP-933L Ler 0.045 3.04E03 0.437 2.11E01 0.074 1.23E01 0.037 2.42E02
Z5108 sepL 148 CP-933L Ler 0.083 3.97E05 0.252 1.21E03 0.065 1.01E01 0.238 5.33E02
Z5109 escD 148 CP-933L PchA  Ler 0.107 5.47E04 0.435 3.59E05 0.105 1.59E01 0.237 3.92E02
Z5110 eae 148 CP-933L PchA  Ler 0.040 2.24E03 0.211 4.34E05 0.061 9.04E02 0.132 3.86E02
Z5111 Z5111 148 CP-933L PchA  Ler 0.056 7.15E03 0.329 1.64E02 0.084 1.48E01 0.081 3.12E02
Z5112 tir 148 tir CP-933L Ler 0.079 2.12E03 0.344 1.40E05 0.103 1.24E01 0.156 5.16E02
Z5113 Z5113 148 CP-933L PchA  Ler 0.072 3.23E04 0.287 1.06E03 0.082 1.26E01 0.155 3.80E02
Z5114 Z5114 148 CP-933L PchA  Ler 0.057 5.71E03 0.312 1.13E03 0.075 1.24E01 0.191 3.64E02
Z5115 Z5115 148 espH CP-933L PchA  Ler 0.071 2.57E04 0.235 2.21E03 0.065 6.92E02 0.224 6.52E02
Z5116 sepQ 148 CP-933L PchA  Ler 0.033 9.11E03 0.156 3.88E04 0.047 6.05E02 0.204 1.28E02
Z5119 escN 148 CP-933L PchA  Ler 0.134 7.62E03 0.388 1.47E04 0.123 1.32E01 0.333 1.32E02
Z5120 escV 148 CP-933L PchA  Ler 0.088 1.01E02 0.285 5.95E04 0.114 1.06E01 0.398 1.91E02
Z5121 Z5121 148 CP-933L PchA  Ler 0.064 1.08E02 0.273 2.96E03 0.092 1.27E01 0.328 8.38E03
Z5123 Z5123 148 CP-933L PchA  Ler 0.139 5.37E03 0.361 1.69E02 0.118 1.16E01 0.176 3.22E02
Z5124 escJ 148 CP-933L PchA  Ler 0.081 4.69E03 0.272 5.05E04 0.111 7.00E02 0.259 4.04E02
Z5125 Z5125 148 CP-933L PchA  Ler 0.047 1.05E02 0.233 1.79E02 0.085 1.01E01 0.27 9.86E03
Z5126 escC 148 CP-933L PchA  Ler 0.112 6.86E03 0.307 7.42E03 0.087 1.04E01 0.173 2.91E02
Z5127 cesD 148 CP-933L PchA  Ler 0.075 6.20E03 0.237 2.02E02 0.062 8.64E02 0.178 1.73E02
Z5128 Z5128 148 CP-933L PchA  Ler 0.04 5.09E03 0.177 5.26E03 0.056 7.90E02 0.179 5.51E02
Z5129 Z5129 148 CP-933L PchA  Ler 0.083 1.06E03 0.244 8.03E04 0.076 8.62E02 0.204 2.14E02
Z5131 Z5131 148 CP-933L PchA  Ler 0.035 3.05E03 0.256 1.10E02 0.076 1.09E01 0.397 3.56E03
Z5132 escU 148 CP-933L PchA  Ler 0.025 1.07E02 0.14 4.94E03 0.044 2.57E02 0.463 7.15E02
Z5133 escT 148 CP-933L PchA  Ler 0.043 8.33E07 0.178 1.54E02 0.088 4.77E02 0.3 1.82E03
Z5134 escS 148 CP-933L PchA  Ler 0.088 1.57E03 0.18 1.67E02 0.085 7.07E02 0.374 4.24E02
Z5135 escR 148 CP-933L PchA  Ler 0.117 2.84E04 0.179 2.74E02 0.086 4.95E02 0.304 4.41E04
Z5137 Z5137 148 CP-933L PchA  Ler 0.14 1.12E02 0.216 2.29E02 0.091 2.44E02 0.148 1.09E05
Z5139 Z5139 148 CP-933L PchA  Ler 0.233 2.46E03 0.295 4.66E02 0.143 4.93E03 0.173 3.92E05
Z5142 Z5142 148 espG CP-933L PchA  Ler 0.089 9.46E04 0.221 1.72E03 0.092 3.57E02 0.298 7.90E02
Z5953b yjiY 12.27 2.22E06 4.792 2.84E03 4.997 2.60E02 2.653 1.66E01
Z6024 Z6024 71 nleA CP-933P PchA  Ler 0.077 1.49E03 0.196 3.13E03 0.075 8.08E02 0.38 6.11E02
Z4668 rpsM 0.673 0.015 0.926 0.159 1.103 0.219 0.965 0.585
Z3013b fliC 4.305 0.061 33.830 0.020 5.064 0.111 0.311 0.340
a Transcription of rpsM and transcription of fliC were included as controls.
b Gene upregulated by inhibitor treatment.
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LexA regulon were not significantly repressed in inhibitor-
treated cultures. It therefore seems unlikely that inhibition of
LexA derepression is the mechanism of transcriptional silenc-
ing of the T3SS (see Fig. S1C in the supplemental material).
Whereas the majority of the regulators showed no changes in
expression when the inhibitors were added, the LEE regulator
genes ler (encoding Ler), grlA, and grlR all showed consistent
downregulation upon treatment with all four compounds. The
finding that ler and grlAR are downregulated coordinately is con-
sistent with previous reports (6, 12). The pchABC genes also
showed some changes, particularly after addition of ME0055, the
most potent inhibitor of Tir secretion. The T3S regulators Ler
and PchA have been shown to bind and positively activate tran-
scription of a number of genes in OIs (1). A comparison of the
genes affected by inhibitor treatment and the Ler-PchA regulon
defined by Abe and coworkers (1) indicates that there is signifi-
cant overlap between these regulons (see Table S1 in the supple-
mental material). Fifty-two of 100 genes repressed by ME0052, 39
of 60 genes repressed by ME0053, 11 of 21 genes repressed by
ME0054, and 6 of 19 genes repressed by ME0055 are bound or
regulated by Ler or PchA. PchA binds and positively regulates a
number of secreted effectors encoded on horizontally acquired
elements, such as a cryptic prophage. Table S1 in the supplemen-
tal material shows that a number of the non-LEE-encoded effec-
tors are repressed by inhibitor treatment, indicating that in addi-
tion to repressing transcription of the T3SS machinery,
translocated effectors not encoded by the LEE are also down-
regulated.
Iron starvation has been proposed to play a key role in the
virulence-attenuating properties of the T3S inhibitors de-
scribed here in Chlamydia pneumoniae (36). Related com-
pounds have been shown to sequester iron, and addition of a
high concentration (200 M) of iron sulfate or iron chloride to
inhibitor-treated cultures can reverse the inhibitory effects of
these compounds. Our data support this finding since addition
of 200 M FeSO4 reversed the effect of ME0053 in TUV-930
(data not shown). In order to assess the effects of the inhibitors
on iron availability in the cell, we used the RegulonDB data-
base definition of the Fur regulon in E. coli K-12 (8; http:
//regulondb.ccg.unam.mx/). None of 16 genes known to be Fur
regulated were significantly affected by addition of an inhibitor
(see Fig. S1D in the supplemental material). Similarly, when
the GO ontology “iron transport” subset of 29 genes (GO6826)
was used, no genes involved in iron transport were affected by
all four inhibitors, indicating that intracellular iron supplies are
not affected at the concentration of inhibitor used in this study
(see Fig. S1E in the supplemental material). It should be noted
that the growth medium contained 250 nM Fe(NO3)2, which
might have masked any effects on iron availability. Finally, to
confirm that an inhibitor at a concentration of 20 M did
not modulate gene expression by perturbing the bacterial
growth rate, we analyzed both the rpoS (Z4049) and groEL
FIG. 3. (A) Effects of ME0052, ME0053, ME0054, and ME0055 on transcription of the LEE. The changes (log2) in the transcription of
treated cultures compared with cultures treated with DMSO alone are shown for all of the genes in the LEE (OI-148A). The strong
repressive effects of the compounds on LEE1 to LEE5 can be contrasted to the effects on the prophage 933L genes indicated on the left.
(B) Reference diagram of the LEE from strain EDL933, showing the five polycistronic operons (LEE1 to LEE5). The diagram was produced
using Colibase (http://xbase.bham.ac.uk/colibase/).
TABLE 4. Total numbers of genes with 2-fold changes (3-fold
changes for inhibitors ME0052 and ME0054) in transcription for
the four inhibitors and numbers of genes in the OI and a
cryptic prophage (CP-933)
Inhibitor or
genome
Total no.
of genes
OI genes CP-933 genes
No. of
genes P
a No. of
genes P
a
ME0052 181 118 7.2e32 94 1.3e52
ME0053 72 46 8.2e13 41 1.5e25
ME0054 23 18 2.2e08 18 1.2e19
ME0055 36 7 0.22 7 0.41
Genomeb 5,481 1,449 0.98 727 0.98
a P values were calculated using a chi-square test with Yates correction.
Expected values were generated from the total numbers of OI or CP-933
genes in the genome as described by Perna et al. (27) and are expressed as
relative proportions of the total number of genes with a twofold change. The
P values represent the significance of the bias toward OI or CP-933 genes.
b Total numbers of genes in E. coli O157 EDL933 (annotation of Perna et al.
	27
).
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genes (Z5748) and found that they were not significantly af-
fected by addition of the four compounds (data not shown).
While the majority of transcriptional changes conserved across
all four inhibitors were downregulated, pspDC and yjiY were sig-
nificantly upregulated by inhibitor treatment (P 0.05). pspBC is
part of the phage shock protein response, and analysis of the
transcriptional data indicated that the rest of the operon, includ-
ing pspAB and pspE, was induced, albeit to a lesser degree. The
phage shock protein response has previously been reported to be
induced by loss of the proton motive force, notably through in-
sertion of the filamentous phage pIV secretin. This response is
also essential for membrane insertion of the YscC secretin of the
Yersinia T3SS (5). yjiY was also consistently induced in inhibitor-
treated cultures; however, there has been little characterization of
this protein apart from its induction under stress conditions, such
as growth in urine and pH stress (17, 37).
Reporter gene analysis. For independent verification of the
array data, we used a series of GFP reporter fusions to analyze
the effects of the inhibitors on the promoters of the LEE and
the rpsM gene as a control. Previous work has shown that the
majority of LEE genes are transcribed by promoters that en-
compass five polycistronic operons designated LEE1 to LEE5
(20). We therefore used LEE1 to LEE5 plasmid-based GFP
reporter fusions (34) to verify the transcriptome data and show
inhibition of LEE transcription. The concentration of each
compound (20 M) was same as that used for transcriptional
profiling so that the data could be directly compared. Expres-
sion of LEE1 to LEE5 was repressed in the presence of the
inhibitors, consistent with the microarray results (Table 5). The
control fusion, consisting of the rpsM promoter which drives
expression of the small rRNA protein, was not affected by
addition of the inhibitors, which is also consistent with the
microarray findings (Table 4).
Effect on A/E lesion formation. The Western analyses dem-
onstrated that compound ME0055 was the most effective of the
four compounds for reducing expression and, therefore, secre-
tion of the key virulence-associated effector protein Tir. How-
ever, all the data presented above were obtained with in vitro
assays, the majority of which used tissue culture medium to
stimulate expression of the LEE. This raised the question of
whether the inhibitor would affect the ability of E. coli O157 to
bind host cells and form A/E lesions. Using a bovine epithelial
cell line (EBL), we analyzed the ability of TUV-930 to form
A/E lesions. Following a 6-h infection period, we observed that
bacteria cultured in the presence of 20 M ME0055 were still
capable of condensing host cell actin and forming distinctive ped-
estals (Fig. 5B). However, it was evident that the proportion of
bacteria forming A/E lesions was reduced compared to the pro-
portion in the culture treated with DMSO alone (Fig. 5A). In
order to quantify any differences, we used Volocity Quantification
(Improvision) to identify bacteria associated with areas of dense
actin in the three-dimensional images. This was achieved by using
size and fluorescence intensity thresholds to identify bacteria,
condensed actin, and then areas of clear colocalization. This au-
tomated approach allowed us to collate the data from 15 individ-
ual fields collected across triplicate repeats of the experiment.
These analyses indicated that after 6 h, 28%  3% of bacteria
FIG. 4. Effects of ME0052, ME0053, ME0054, and ME0055 on the transcription of known regulators of the LEE. The changes (log2) in
transcription of treated cultures compared with cultures treated with DMSO alone are shown for the 17 regulators that were characterized.
TABLE 5. Analysis of promoter-GFP constructs for cultures in
MEM-HEPES in presence and absence of the
small-molecule inhibitors
Plasmid Promoter
Ratiosa
ME0052 ME0053 ME0054 ME0055
pAJR71 LEE1 0.23 0.25 0.25 0.38
pAJR72 LEE2 0.38 0.55 0.21 0.120
pAJR73 LEE3 0.21 0.41 0.16 0.328
pAJR74 LEE4 0.21 0.34 0.17 0.17
pAJR75 LEE5 0.19 0.45 0.19 0.25
pAJR145 rpsM 0.98 0.99 1.1 0.98
a The ratios were calculated by dividing the fluorescence value for the strain
cultured in the presence of the inhibitor by the fluorescence value for the strain
cultured in the absence of the inhibitor. All values were corrected for the
background by subtracting the fluorescence value for the strain transformed with
pAJR70 (promoterless gfp) obtained at the same optical density.
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treated with ME0055 were associated with A/E lesions (Fig. 5b).
This value was significantly less (P 0.001) than the value for the
culture treated with DMSO alone, in which 69%  16% of the
bacteria formed A/E lesions (Fig. 5A).
Effect on LEE1 gene expression and flagellum production
during contact with bovine epithelial cells. The reduction in
the ability of TUV-930 to form A/E lesions implied that addi-
tion of compound ME0055 resulted in suppression of LEE
expression even during contact with host epithelial cells. To
examine this result further, we performed cell binding assays
using TUV-930 transformed with a LEE1::GFP reporter plas-
mid (pAJR71) that allowed measurement of ler expression
during contact with epithelial cells. Additionally, our observa-
tion that the inhibitors affected grlA and grlR expression im-
plied that flagellum production may be increased as these
regulators have been shown to cross-regulate the LEE and
flagella (12). Furthermore, recent work has shown that during
the cell infection process, E. coli O157 undergoes a rapid
temporal shift from expression of H7 flagella to production of
the T3SS (15). We therefore asked if the inhibitory compounds
affected this transition. To examine this possibility, immuno-
fluorescence antibody staining was used to examine any effects
on the expression of H7 flagella. After addition of the bacteria
to the EBL cell line, the expression of LEE1::GFP was deter-
mined at fixed time points by addition of 4% PFA. Figure 6
shows that 60 min after addition of TUV-930 to the EBL cell
line there was a significant difference in LEE1::GFP expression
when ME0055-treated cells were compared with the culture
treated with DMSO alone. Both the proportion of bacteria
expressing GFP and the GFP intensity in bacteria which were
“GFP positive” were found to be significantly different. Over
the time course, the GFP levels decreased in the bacteria
treated with DMSO alone. The ME0055-treated cells exhibited
a similar pattern in that the GFP levels decreased throughout
the time course, but both the proportion of GFP-positive bacteria
and the GFP intensity of these bacteria were observed to be
consistently reduced compared to the results for the culture
treated with DMSO alone. Staining for H7 revealed that addition
of ME0055 led to an increase in flagellum expression compared
to the results for the bacteria treated with DMSO alone. Over the
time course, the level of H7 expression increased from 20% of the
population at 60 min to 40% at 120 min and was still high (30%)
5 h after addition of the bacteria to the eukaryotic cell line. These
data indicate that addition of ME0055 suppresses LEE1 expres-
sion, even during host cell contact, and leads to an increase in H7
expression. Clearly, both these observations correlate well with
the reduction in A/E lesion formation.
DISCUSSION
The central role of T3SSs in the pathogenesis of many bac-
terial species provides the impetus to develop strategies that
interfere with their function. To do this, “virulence blockers”
have been described that selectively target the expression or
function of T3SSs in a number of bacterial species, including Y.
pseudotuberculosis, Salmonella serovar Typhimurium, C. pneu-
moniae, and EPEC. There is marked conservation of elements
of the T3SS between EPEC and EHEC, yet the transcriptional
control of these systems is varied and many regulators of T3S
are encoded by horizontally acquired DNA in these polylyso-
genic pathogens (31, 40, 41). The variation in T3S regulation
observed for isolates of EHEC O157 has also been suggested
to play an important role in the epidemiology of this pathogen
(4, 16). As salicylidene acylhydrazide inhibitors of T3S repress
FIG. 5. Addition of ME0055 affects formation of A/E lesions on
EBL bovine epithelial cells. Bacteria were cultured in the presence
of DMSO (A) or 20 M ME0055 (B) and added to the EBL cell
line. After 6 h, the cells were fixed using 4% PFA and stained to
reveal host cell actin (red) (TRITC-phalloidin) and bacteria (green)
(anti-O157 and Alexifluor 488-conjugated secondary antibodies).
Composite, overlay images obtained using 15 z stack sections are
shown.
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transcription of the T3SS, a detailed investigation of the effects
of these compounds on EHEC O157 is warranted. In this study
we attempted to address two questions. First, is the T3S inhi-
bition that has been demonstrated in other pathogens observed
in EHEC O157, and is there serotype- and strain-specific vari-
ation in the responses? Second, are there conserved and/or
inhibitor-specific transcriptional responses that may help us
understand the mode of action?
In agreement with the previous studies examining repres-
sion of bacterial T3SS, we observed that all four compounds
studied were capable of inhibiting secretion of virulence
proteins from E. coli O157:H7. Addition of higher concen-
FIG. 6. Effect of ler gene expression during contact with EBL bovine epithelial cells in DMSO-treated (A1 to A4) or ME0055-treated (B1
to B4) bacteria. Bacteria transformed with the LEE1::GFP reporter plasmid (pAJR71) were added to EBL cells, and the samples were fixed
using 4% PFA and visualized using anti-O157:H7 antibodies and Alexifluor 555-conjugated secondary antibodies. The time points analyzed
were 60 min (A1 and B1), 120 min (A2 and B2), 180 min (A3 and B3), and 300 min (A4 and B4) after bacterial addition. Composite, overlay
images obtained using 20 0.1-m z stack sections are shown. (C) Quantification of LEE1::GFP expression during bacterial contact with host
cells. Minus and plus signs indicate samples that contained DMSO and samples that contained ME0055, respectively. The graphs show the
amounts of GFP per bacterial cell (expressed in relative fluorescence units) for the time points described above. The proportion of bacteria
that showed GFP expression greater than a threshold level (GPF ve) and the proportion of bacteria that were found to express flagella
(Flagella ve) are also indicated (red bars).
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trations of the compounds had marked effects on the growth
rate and were not used in subsequent experiments. At a
concentration of 20 M, inhibition of Tir and EspD was
observed without major effects on the GroEL level or the
growth rate. Further, the relative transcription levels of the
rpoS (Z4049) and groEL genes (Z5748) were not found to be
significantly (P  0.05) affected by addition of any of the
four compounds. This indicated that the transcriptional
changes observed could not be attributed simply to changes
in the bacterial growth rate.
The repression of T3S in a diverse range of pathogens
suggests that there is a common, conserved target. The most
conserved region of the T3SS is the basal apparatus proteins,
and this region has recently been proposed to be the target of
related inhibitors in Shigella flexneri (38). We noted that the
results presented in the study of Veenendaal et al. do not
contradict our findings as these authors showed that treatment
with an inhibitor decreased the amount of the basal apparatus
in the membrane, suggesting that inhibition occurs at a very
early stage of assembly and insertion or at the level of tran-
scription. We anticipate that if the inhibitors bind proteins of
the T3S complex, all related strains with conserved basal ap-
paratus proteins would likely be affected by the compounds to
similar extents, if not the same extent. In the present study we
found significant variation in the level of inhibition of T3S
between strains. We propose that this reflects inhibition
through a more variable route, such as the repertoire of LEE
regulators in any one strain. Indeed, we previously reported
that the EHEC O157:H7 Sakai strain differed from the EHEC
O26:H- strain 193 by the presence of the ETT2-encoded neg-
ative regulators of LEE Z3720 and Z3734 (41), and variability
in expression of the pchABCX genes has recently been de-
scribed (40). We therefore favor a model of inhibition involv-
ing transcriptional repression of T3S that would be consistent
with the strain variation and the global transcriptional changes
that we observed.
To examine the effect of the inhibitors on gene regulation,
we examined the transcriptional profiles of cells treated with
all four compounds. The results presented here indicate that
ME0052 to ME0055 represses transcription of the LEE- and
non-LEE-encoded virulence factors. Surprisingly, ME0052,
which was the least effective compound for limiting Tir secre-
tion, had the greatest effect on global gene transcription. Con-
versely, ME0055 showed much greater repression of protein
secretion but more limited global repression of transcription.
Perhaps critically, transcription of espA, encoding the T3 trans-
location filament, was strongly repressed by ME0055, and this
may indicate that repression of the translocon can have a more
significant overall effect on protein secretion.
Related salicylidene acylhydrazide compounds have been
shown to repress expression of the T3SS in C. pneumoniae, a
phenotype that can be reversed by addition of high concentra-
tions of iron. These findings are supported by our results which
show that addition of 200 M FeSO4 can reverse the effect of
compound ME0053 in TUV-930. In order to assess the effects
of these compounds on iron availability in the cell, we analyzed
the transcriptome to look for changes that would indicate iron
starvation. The ferric uptake regulator (Fur) is a key regulator
of iron uptake under iron starvation conditions, repressing
expression of iron uptake pathways and virulence determinants
such as Shiga toxin under iron-replete conditions. We did not
observe marked changes in the Fur regulon or in genes asso-
ciated with iron transport in inhibitor-treated cells (see Fig.
S2D and E in the supplemental material), indicating that they
were not iron starved.
Repressed transcripts were biased toward OI genes, partic-
ularly those in a cryptic prophage (Table 4), and many of these
genes encode secreted effectors of the T3SS. One explanation
for the bias toward repression of the OI genes is that one or
more key regulators of horizontally acquired genes are affected
by addition of the compounds. On this basis we examined the
expression of regulators known to play a role in coordinate
expression of virulence genes, including H-NS, LexA, Fur,
PchA, and Ler. There was little indication in the transcrip-
tional data that H-NS and LexA regulons were significantly
affected by inhibitor treatment (see Fig. S1C in the supplemen-
tal material). In contrast, PchA and Ler were significantly
repressed by inhibitor treatment.
Recent transcriptional profiling and chromatin immuno-
precipitation experiments performed by Abe and coworkers
(1) have shown that both Ler and PchA can globally regulate
transcription of the LEE and a significant number of non-
LEE-encoded effectors. For many of these recently identi-
fied effectors this is the first indication of a regulatory mech-
anism that coordinates transcription with the LEE.
Transcriptional profiling of inhibitor-treated cells indicated
that repression of transcription is not confined to the LEE
but extends to pathogenicity island-encoded virulence de-
terminants, such as the non-LEE-encoded effectors, ele-
ments of the type II secretion pathway, and hemolysins
encoded ion pO157. Comparison of the Ler-PchA regulon
with genes conserved across all four inhibitor treatments
showed that 6 of the 12 non-LEE genes repressed by all
inhibitor treatments are bound or regulated by PchA and/or
Ler, and 30 of 166 genes are significantly repressed by at
least one inhibitor treatment. There are PchA homologues
in many pathogenic and nonpathogenic bacteria, including
Yersinia (YpsIP31758_0776), Salmonella (NP_700416.1), Shi-
gella (NP_599072.1), EPEC (PerC), uropathogenic E. coli
(NP_754054.1 and NP_755073.1), and nonpathogenic E. coli
(yfdN) (29), and they may contribute to expression of horizon-
tally acquired elements in these bacteria. Our results suggest
that modulating the activity of the PchA regulon may contrib-
ute to the broad antivirulence effects of the inhibitors in EHEC
and, potentially, in other pathogenic bacteria. Clearly, inhibi-
tion of Pch function through changes in its expression or ac-
tivity is one possible mechanism to explain how numerous OI
genes are coordinately downregulated by addition of the in-
hibitors. Simultaneous repression of a number of virulence
determinants could contribute to the effectiveness of these
inhibitors to limit colonization of cattle and disease in humans.
In conclusion, we have shown that salicylidene acylhydra-
zide inhibitors selectively inhibit the transcription of the
T3SS and other OI genes of E. coli O157. Our data suggest
that in E. coli O157 these compounds act through regulators
rather than directly at the level of the T3SS apparatus. We
have also found inhibitor- and strain-specific effects that
should be taken into consideration when the mode of action
and therapeutic potential of such molecules are determined.
Our ongoing studies are using a combination of transposon
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mutagenesis screening and affinity purification to identify
possible protein targets.
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